Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Sarah Milgrom

Concepts (363)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Hodgkin Disease
41
2026
171
11.970
 Why?
Radiotherapy, Intensity-Modulated
17
2026
141
4.120
 Why?
Positron Emission Tomography Computed Tomography
17
2026
117
3.820
 Why?
Tumor Burden
7
2026
319
2.330
 Why?
Fluorodeoxyglucose F18
8
2026
156
2.330
 Why?
Radiotherapy
14
2025
206
2.200
 Why?
Lymphoma
10
2025
232
2.100
 Why?
Radiotherapy Planning, Computer-Assisted
15
2026
149
2.070
 Why?
Antineoplastic Combined Chemotherapy Protocols
33
2026
1953
2.060
 Why?
Whole-Body Irradiation
3
2026
76
1.920
 Why?
Radiation Injuries
9
2025
151
1.890
 Why?
Radiotherapy Dosage
18
2026
289
1.710
 Why?
Central Nervous System Neoplasms
9
2021
173
1.710
 Why?
Radiopharmaceuticals
6
2023
194
1.620
 Why?
Hematologic Neoplasms
2
2026
161
1.560
 Why?
Lymphoma, Non-Hodgkin
6
2024
124
1.450
 Why?
Neoplasm Staging
31
2026
1462
1.410
 Why?
Lymphoma, Large B-Cell, Diffuse
8
2024
192
1.270
 Why?
Sarcoma
2
2023
205
1.200
 Why?
Neoplasm Recurrence, Local
13
2023
1137
1.180
 Why?
Salvage Therapy
11
2024
162
1.180
 Why?
Mediastinal Neoplasms
5
2021
51
1.090
 Why?
Endometrial Neoplasms
4
2014
208
1.080
 Why?
Neoplasms
7
2026
2875
1.060
 Why?
Prognosis
24
2026
4282
1.060
 Why?
Hematopoietic Stem Cell Transplantation
7
2024
675
1.040
 Why?
Combined Modality Therapy
22
2024
1266
1.040
 Why?
Radiotherapy, Adjuvant
7
2024
222
0.980
 Why?
Positron-Emission Tomography
9
2025
323
0.950
 Why?
Humans
122
2026
144759
0.940
 Why?
Neoplasms, Radiation-Induced
2
2026
99
0.930
 Why?
Rhabdomyosarcoma
2
2024
64
0.930
 Why?
Neoplasms, Second Primary
2
2026
100
0.900
 Why?
Sarcoma, Ewing
2
2024
102
0.890
 Why?
Proton Therapy
2
2026
15
0.870
 Why?
Disease Progression
7
2024
2847
0.840
 Why?
Clinical Trials as Topic
2
2026
1053
0.800
 Why?
Radiation
2
2020
24
0.800
 Why?
Child
28
2026
22633
0.790
 Why?
Craniopharyngioma
1
2024
77
0.790
 Why?
Young Adult
36
2026
14105
0.790
 Why?
Radiation Exposure
1
2023
63
0.770
 Why?
Pituitary Neoplasms
1
2024
190
0.750
 Why?
Adenocarcinoma
3
2014
928
0.730
 Why?
Lymphoma, Follicular
5
2020
56
0.730
 Why?
Salivary Glands
2
2021
36
0.720
 Why?
Smiling
1
2021
6
0.710
 Why?
Adolescent
33
2026
22428
0.700
 Why?
Xerostomia
1
2021
13
0.690
 Why?
Retrospective Studies
39
2026
17066
0.680
 Why?
Tooth Abnormalities
1
2021
16
0.680
 Why?
Brachytherapy
1
2021
134
0.650
 Why?
Face
1
2021
173
0.630
 Why?
Cancer Survivors
2
2026
327
0.630
 Why?
Chemoradiotherapy
9
2021
237
0.630
 Why?
Doxorubicin
13
2025
397
0.620
 Why?
Bleomycin
9
2025
253
0.620
 Why?
Aged, 80 and over
23
2026
8265
0.610
 Why?
Vinblastine
9
2025
75
0.610
 Why?
Intraocular Lymphoma
2
2016
3
0.600
 Why?
Dacarbazine
9
2025
100
0.600
 Why?
Aged
43
2026
25913
0.590
 Why?
Adult
54
2026
40449
0.590
 Why?
Infertility, Female
2
2025
112
0.590
 Why?
Middle Aged
51
2026
35875
0.580
 Why?
Lymphoma, B-Cell, Marginal Zone
4
2019
19
0.570
 Why?
Organs at Risk
4
2026
37
0.570
 Why?
Rectal Neoplasms
3
2016
156
0.560
 Why?
Female
63
2026
78271
0.540
 Why?
Radiotherapy, Image-Guided
4
2026
39
0.540
 Why?
Cerebellar Neoplasms
1
2020
177
0.540
 Why?
Breast Neoplasms
6
2026
2452
0.530
 Why?
Medulloblastoma
1
2020
215
0.530
 Why?
Recurrence
9
2020
1135
0.510
 Why?
Meningeal Neoplasms
1
2018
94
0.500
 Why?
Leukemia, Biphenotypic, Acute
1
2016
4
0.500
 Why?
Male
55
2026
72315
0.490
 Why?
Leukemia, Myeloid, Acute
2
2023
682
0.490
 Why?
Patient Satisfaction
1
2020
704
0.470
 Why?
Head and Neck Neoplasms
1
2021
558
0.470
 Why?
Treatment Outcome
26
2026
11679
0.460
 Why?
Graft vs Host Disease
2
2024
264
0.460
 Why?
Mediastinum
4
2026
23
0.450
 Why?
Eye Diseases
1
2016
94
0.440
 Why?
Brain Neoplasms
3
2023
1318
0.440
 Why?
Follow-Up Studies
16
2025
5408
0.430
 Why?
Survival Rate
12
2021
2089
0.420
 Why?
Disease-Free Survival
12
2020
769
0.410
 Why?
Glycolysis
3
2023
339
0.400
 Why?
Endometrium
1
2013
61
0.390
 Why?
Peritoneal Cavity
1
2013
30
0.390
 Why?
Digestive System Surgical Procedures
1
2014
109
0.380
 Why?
Palate, Hard
1
2012
5
0.380
 Why?
Lymphoma, B-Cell
3
2021
132
0.380
 Why?
Stomach Neoplasms
3
2019
126
0.380
 Why?
Chemoradiotherapy, Adjuvant
3
2019
44
0.370
 Why?
Mastectomy, Simple
1
2012
1
0.370
 Why?
Image Enhancement
1
2013
199
0.360
 Why?
Neoadjuvant Therapy
2
2016
462
0.350
 Why?
Sentinel Lymph Node Biopsy
1
2012
118
0.350
 Why?
Carcinoma, Lobular
1
2012
56
0.350
 Why?
Carcinoma, Ductal, Breast
1
2012
88
0.350
 Why?
Adrenal Gland Neoplasms
1
2012
91
0.330
 Why?
Child, Preschool
8
2026
11787
0.330
 Why?
Radiotherapy, Conformal
2
2026
74
0.320
 Why?
Biopsy
6
2020
1075
0.310
 Why?
Disease Management
6
2019
645
0.310
 Why?
Cellulitis
1
2009
53
0.300
 Why?
Tomography, X-Ray Computed
7
2023
2730
0.300
 Why?
Antineoplastic Agents
6
2025
2194
0.290
 Why?
Carcinoma, Squamous Cell
1
2014
641
0.290
 Why?
Kaplan-Meier Estimate
7
2020
965
0.280
 Why?
Lymphocytes
3
2020
382
0.280
 Why?
Lymphoma, Mantle-Cell
2
2019
32
0.270
 Why?
Organ Sparing Treatments
2
2026
38
0.270
 Why?
Coronary Artery Disease
2
2026
741
0.260
 Why?
Consensus
3
2024
488
0.250
 Why?
Survival Analysis
6
2020
1382
0.240
 Why?
Cardiotoxicity
2
2023
33
0.240
 Why?
Lung Neoplasms
3
2026
2637
0.240
 Why?
Pregnancy Complications, Neoplastic
2
2017
63
0.240
 Why?
Testicular Neoplasms
2
2018
113
0.240
 Why?
Multiple Myeloma
2
2020
291
0.240
 Why?
Credentialing
1
2026
21
0.240
 Why?
Patient Selection
2
2022
719
0.230
 Why?
Radiation Pneumonitis
2
2016
31
0.230
 Why?
Pelvic Neoplasms
1
2025
24
0.230
 Why?
Heart
3
2018
636
0.220
 Why?
Urinary Tract
1
2025
48
0.220
 Why?
Urodynamics
1
2025
47
0.220
 Why?
Lymph Node Excision
2
2019
173
0.220
 Why?
Antimetabolites, Antineoplastic
2
2017
105
0.220
 Why?
Risk Factors
6
2026
10779
0.220
 Why?
Risk Assessment
6
2023
3671
0.220
 Why?
Leukemia
2
2017
245
0.210
 Why?
United States
5
2026
15966
0.210
 Why?
Lower Urinary Tract Symptoms
1
2025
59
0.210
 Why?
Transplantation, Haploidentical
1
2024
23
0.210
 Why?
Radiation Oncology
1
2025
88
0.210
 Why?
Central Nervous System
3
2021
281
0.210
 Why?
Magnetic Resonance Imaging
4
2019
3863
0.210
 Why?
Uterus
1
2025
226
0.200
 Why?
Quality Assurance, Health Care
1
2025
340
0.200
 Why?
Virtual Reality
1
2025
77
0.200
 Why?
Lymphadenopathy
1
2023
8
0.200
 Why?
Lymphatic Metastasis
3
2014
333
0.200
 Why?
Cord Blood Stem Cell Transplantation
1
2024
103
0.200
 Why?
Transplantation Conditioning
1
2024
186
0.190
 Why?
Comprehension
1
2025
180
0.190
 Why?
Neoplasm Grading
4
2019
307
0.190
 Why?
Remission Induction
3
2018
307
0.190
 Why?
Protons
2
2020
95
0.180
 Why?
Brain Stem Neoplasms
1
2023
87
0.180
 Why?
Bone Neoplasms
1
2024
253
0.180
 Why?
Gastric Mucosa
2
2019
52
0.180
 Why?
Radiometry
2
2019
56
0.180
 Why?
Mitogen-Activated Protein Kinase 7
1
2021
16
0.180
 Why?
Chemotherapy, Adjuvant
2
2013
421
0.180
 Why?
Cohort Studies
6
2024
5960
0.180
 Why?
Transplantation, Autologous
3
2018
290
0.170
 Why?
Survivors
2
2023
520
0.170
 Why?
Multimodal Imaging
3
2017
124
0.170
 Why?
Postoperative Complications
1
2014
2919
0.170
 Why?
Poly(ADP-ribose) Polymerases
1
2021
86
0.170
 Why?
Radium
1
2020
4
0.170
 Why?
Artificial Intelligence
1
2025
365
0.170
 Why?
Imaging, Three-Dimensional
1
2025
583
0.170
 Why?
Breath Holding
2
2017
10
0.170
 Why?
Long Term Adverse Effects
1
2020
13
0.160
 Why?
Cranial Irradiation
2
2023
85
0.160
 Why?
Patient Education as Topic
1
2025
780
0.150
 Why?
Skin Neoplasms
2
2018
847
0.150
 Why?
Stem Cell Transplantation
2
2018
191
0.150
 Why?
Plasmacytoma
1
2019
19
0.150
 Why?
Cardiology
1
2022
353
0.150
 Why?
Postoperative Care
2
2019
288
0.150
 Why?
CD4-CD8 Ratio
1
2018
23
0.150
 Why?
Radiation Dosage
1
2020
192
0.140
 Why?
Mycosis Fungoides
1
2018
62
0.140
 Why?
Methotrexate
2
2017
240
0.140
 Why?
Electrons
1
2018
88
0.140
 Why?
Breast Neoplasms, Male
1
2018
29
0.140
 Why?
Glioma
1
2023
425
0.140
 Why?
Area Under Curve
1
2019
330
0.140
 Why?
Peritoneal Neoplasms
1
2019
103
0.140
 Why?
Radiotherapy Setup Errors
1
2017
3
0.130
 Why?
Platelet Count
1
2017
96
0.130
 Why?
Autografts
1
2018
55
0.130
 Why?
Hypothyroidism
1
2018
67
0.130
 Why?
Craniospinal Irradiation
1
2017
5
0.130
 Why?
Dendritic Cell Sarcoma, Follicular
1
2017
4
0.130
 Why?
Eye Neoplasms
1
2017
30
0.130
 Why?
Leukocyte Count
1
2017
316
0.130
 Why?
Vincristine
4
2019
140
0.130
 Why?
Osteogenesis Imperfecta
2
2007
14
0.130
 Why?
Spinal Cord Diseases
1
2017
41
0.120
 Why?
Uncertainty
1
2017
144
0.120
 Why?
Pentostatin
1
2016
4
0.120
 Why?
Neoplasm, Residual
1
2017
139
0.120
 Why?
Photopheresis
1
2016
9
0.120
 Why?
Axilla
2
2017
51
0.120
 Why?
Methylprednisolone
1
2016
64
0.120
 Why?
Predictive Value of Tests
3
2022
2115
0.120
 Why?
Prospective Studies
5
2025
7990
0.120
 Why?
Plasmablastic Lymphoma
1
2015
8
0.120
 Why?
Confidence Intervals
1
2016
333
0.120
 Why?
Radiographic Image Interpretation, Computer-Assisted
1
2016
121
0.120
 Why?
Collagen Type I
2
2007
147
0.120
 Why?
Caregivers
2
2025
1049
0.120
 Why?
Fatal Outcome
1
2016
307
0.110
 Why?
Abortion, Spontaneous
1
2016
115
0.110
 Why?
Congenital Abnormalities
1
2016
104
0.110
 Why?
Antibiotics, Antineoplastic
1
2016
139
0.110
 Why?
Hysterectomy
2
2013
137
0.110
 Why?
Anxiety
1
2023
1109
0.110
 Why?
Tacrolimus
1
2016
196
0.110
 Why?
Transplantation, Homologous
1
2016
415
0.110
 Why?
Proportional Hazards Models
4
2020
1325
0.110
 Why?
Drug Resistance, Neoplasm
2
2019
881
0.110
 Why?
Blood Platelets
1
2017
400
0.100
 Why?
Biomarkers
4
2021
4271
0.100
 Why?
Risk
1
2016
911
0.100
 Why?
Etoposide
3
2018
166
0.100
 Why?
Age Factors
1
2021
3333
0.100
 Why?
Receptors, Progesterone
2
2014
356
0.100
 Why?
Cyclophosphamide
3
2019
266
0.100
 Why?
Kidney Neoplasms
1
2018
412
0.100
 Why?
Rituximab
3
2019
209
0.100
 Why?
Carboplatin
1
2013
160
0.100
 Why?
Spinal Cord
1
2015
380
0.090
 Why?
Anti-Inflammatory Agents
1
2016
474
0.090
 Why?
Receptors, Estrogen
2
2014
457
0.090
 Why?
Fluorouracil
1
2013
235
0.090
 Why?
Pelvis
1
2013
124
0.090
 Why?
Lung
2
2016
4109
0.090
 Why?
Carcinoma, Non-Small-Cell Lung
1
2021
1180
0.090
 Why?
Paclitaxel
1
2013
255
0.090
 Why?
Immunoenzyme Techniques
1
2012
200
0.090
 Why?
Immunohistochemistry
1
2016
1716
0.090
 Why?
Neutrophils
1
2017
1134
0.090
 Why?
Health Knowledge, Attitudes, Practice
1
2020
1414
0.090
 Why?
Immunosuppressive Agents
1
2016
846
0.090
 Why?
Cisplatin
1
2013
334
0.080
 Why?
Triple Negative Breast Neoplasms
1
2014
215
0.080
 Why?
Brain
2
2020
2933
0.080
 Why?
Immunotherapy
1
2015
653
0.080
 Why?
Models, Biological
1
2018
1821
0.080
 Why?
Contrast Media
1
2013
488
0.080
 Why?
Polymorphism, Single Nucleotide
1
2016
2145
0.070
 Why?
Patient Compliance
1
2013
588
0.070
 Why?
Dose-Response Relationship, Radiation
2
2020
140
0.070
 Why?
Liver Neoplasms
1
2014
780
0.070
 Why?
Antibodies, Monoclonal, Murine-Derived
2
2019
97
0.070
 Why?
Prednisone
2
2019
221
0.060
 Why?
Cytarabine
2
2018
66
0.060
 Why?
Biomarkers, Tumor
1
2014
1313
0.060
 Why?
Integrins
1
2007
89
0.060
 Why?
Proteoglycans
1
2007
110
0.060
 Why?
Practice Guidelines as Topic
1
2014
1560
0.060
 Why?
Colorectal Neoplasms
1
2014
845
0.060
 Why?
Time Factors
4
2018
7173
0.060
 Why?
Treatment Failure
2
2018
365
0.060
 Why?
Amino Acid Substitution
1
2006
304
0.060
 Why?
Glycine
1
2006
187
0.060
 Why?
Neoplasm Invasiveness
2
2017
508
0.050
 Why?
Fertility Preservation
1
2025
53
0.050
 Why?
Clinical Decision-Making
2
2019
359
0.050
 Why?
American Heart Association
1
2026
350
0.050
 Why?
X-ray Repair Cross Complementing Protein 1
1
2023
13
0.050
 Why?
Intelligence Tests
1
2023
56
0.050
 Why?
Standard of Care
1
2024
80
0.050
 Why?
X-Rays
1
2023
31
0.050
 Why?
Cell- and Tissue-Based Therapy
1
2024
80
0.050
 Why?
Regression Analysis
2
2016
1003
0.050
 Why?
Proto-Oncogene Proteins c-sis
1
2023
39
0.050
 Why?
Analysis of Variance
2
2016
1306
0.050
 Why?
Pregnancy
3
2025
7190
0.050
 Why?
Inducible T-Cell Co-Stimulator Protein
1
2022
10
0.050
 Why?
Cytidine Deaminase
1
2023
59
0.050
 Why?
Phenotype
3
2021
3162
0.050
 Why?
Terminology as Topic
1
2024
255
0.050
 Why?
Brain Stem
1
2023
95
0.050
 Why?
Ribose
1
2021
22
0.040
 Why?
Adenosine Diphosphate
1
2021
84
0.040
 Why?
Troponin T
1
2021
65
0.040
 Why?
Poly (ADP-Ribose) Polymerase-1
1
2021
53
0.040
 Why?
Feedback
1
2021
181
0.040
 Why?
Radiosurgery
1
2024
400
0.040
 Why?
Immunotherapy, Adoptive
1
2024
337
0.040
 Why?
Automation
1
2020
102
0.040
 Why?
Risk Management
1
2020
84
0.040
 Why?
Prevalence
2
2016
2834
0.040
 Why?
Incidence
2
2016
2879
0.040
 Why?
Mesentery
1
2019
45
0.040
 Why?
Infant
2
2025
10034
0.040
 Why?
Workflow
1
2020
184
0.040
 Why?
Neuropsychological Tests
1
2023
1134
0.040
 Why?
Busulfan
1
2018
16
0.030
 Why?
Respiration
1
2019
206
0.030
 Why?
Melphalan
1
2018
42
0.030
 Why?
Safety
1
2020
356
0.030
 Why?
Carmustine
1
2018
52
0.030
 Why?
Algorithms
1
2025
1837
0.030
 Why?
Cone-Beam Computed Tomography
1
2017
30
0.030
 Why?
Inhalation
1
2017
29
0.030
 Why?
Breast
1
2018
158
0.030
 Why?
Subacute Combined Degeneration
1
2017
1
0.030
 Why?
Phosphorylation
1
2021
1732
0.030
 Why?
Photons
1
2017
76
0.030
 Why?
Injections, Spinal
1
2017
120
0.030
 Why?
Time-to-Treatment
1
2019
243
0.030
 Why?
Deoxycytidine
1
2018
221
0.030
 Why?
New York
1
2016
125
0.030
 Why?
Orbit
1
2017
64
0.030
 Why?
Homocysteine
1
2017
151
0.030
 Why?
Lymph Nodes
1
2019
502
0.030
 Why?
Procarbazine
1
2015
9
0.030
 Why?
Genetic Markers
1
2016
331
0.030
 Why?
Observer Variation
1
2016
355
0.030
 Why?
Transforming Growth Factor beta1
1
2016
178
0.030
 Why?
Mutation
1
2007
4089
0.030
 Why?
Folic Acid
1
2017
199
0.030
 Why?
Texas
1
2016
278
0.030
 Why?
Animals
2
2021
38058
0.030
 Why?
Molecular Targeted Therapy
1
2018
432
0.030
 Why?
Mitochondria
1
2021
984
0.030
 Why?
Gastrointestinal Diseases
1
2016
216
0.030
 Why?
Secondary Prevention
1
2016
254
0.030
 Why?
Diagnostic Imaging
1
2017
338
0.030
 Why?
Abortion, Induced
1
2016
110
0.030
 Why?
Drug Administration Schedule
1
2016
779
0.030
 Why?
Pregnancy Outcome
1
2017
476
0.030
 Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
2017
293
0.030
 Why?
Acute Disease
1
2016
1030
0.030
 Why?
Postpartum Period
1
2016
365
0.020
 Why?
Mastectomy
1
2014
162
0.020
 Why?
Multivariate Analysis
1
2016
1539
0.020
 Why?
Diagnosis, Differential
1
2017
1489
0.020
 Why?
CD8-Positive T-Lymphocytes
1
2018
917
0.020
 Why?
Ultrasonography
1
2016
770
0.020
 Why?
CD4-Positive T-Lymphocytes
1
2018
1129
0.020
 Why?
Surveys and Questionnaires
1
2025
6048
0.020
 Why?
Ovariectomy
1
2012
162
0.020
 Why?
Medical Oncology
1
2014
332
0.020
 Why?
Comorbidity
1
2016
1658
0.020
 Why?
Severity of Illness Index
1
2019
2925
0.020
 Why?
Diet
1
2017
1273
0.020
 Why?
Kidney
1
2017
1495
0.020
 Why?
Quality of Life
1
2021
3185
0.020
 Why?
Electronic Health Records
1
2017
1173
0.020
 Why?
Reproducibility of Results
1
2016
3409
0.020
 Why?
Anti-Bacterial Agents
1
2019
1907
0.020
 Why?
Genetic Predisposition to Disease
1
2016
2363
0.020
 Why?
Electrophoresis
1
2006
31
0.020
 Why?
Case-Control Studies
1
2014
3604
0.010
 Why?
DNA Mutational Analysis
1
2007
406
0.010
 Why?
Databases, Genetic
1
2007
248
0.010
 Why?
Protein Structure, Tertiary
1
2007
862
0.010
 Why?
Collagen
1
2007
456
0.010
 Why?
Mice
1
2021
18339
0.010
 Why?
Binding Sites
1
2007
1329
0.010
 Why?
Protein Binding
1
2007
2273
0.010
 Why?
Cells, Cultured
1
2006
4154
0.010
 Why?
Milgrom's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (363) concept(s)
_
Co-Authors Expand Description
See all (39) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)